MAP2K1 and melanoma: Trametinib is a reversible and highly selective allosteric MEK1/MEK2 inhibitor, with an indication for the treatment of different solid tumors characterized by MAPK signaling pathway alterations, such as advanced melanoma [115] or low-grade gliomas [116].